Last reviewed · How we verify
ENC1018 for SAD — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ENC1018 for SAD (ENC1018 for SAD) — EnnovaBio Australia Pharmaceuticals Pty Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ENC1018 for SAD TARGET | ENC1018 for SAD | EnnovaBio Australia Pharmaceuticals Pty Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ENC1018 for SAD CI watch — RSS
- ENC1018 for SAD CI watch — Atom
- ENC1018 for SAD CI watch — JSON
- ENC1018 for SAD alone — RSS
Cite this brief
Drug Landscape (2026). ENC1018 for SAD — Competitive Intelligence Brief. https://druglandscape.com/ci/enc1018-for-sad. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing